Nuo TherapeuticsAURX 33 PS Ratio is 11.04 as of Jul. 11, 2026, which is 52% below its 10-year median of 23.00. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.29 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Nuo Therapeutics ranks worse than 53.33% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nuo Therapeutics's share price is $0.9608.
Nuo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.09. Hence, Nuo Therapeutics's PS Ratio for today is 11.04.
The historical rank and industry rank for Nuo Therapeutics's PS Ratio or its related term are showing as below:
AURX'
s PS Ratio Range Over the Past 10 Years
Min: 0.02 Med: 23 Max: 4025
Current: 11.05
During the past 13 years, Nuo Therapeutics's highest PS Ratio was 4025.00. The lowest was 0.02. And the median was 23.00.
AURX's PS Ratio is ranked worse than 53.33% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs AURX: 11.05
During the past 13 years, Nuo Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 253.00% per year. The lowest was -23.50% per year. And the median was 2.30% per year.
Back to Basics: PS Ratio
Nuo Therapeutics (OTCPK:AURX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Nuo Therapeutics PS Ratio Related Terms
Nuo Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Nuo Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuo Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nuo Therapeutics's Share Price of today is $0.9608. Nuo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Nuo Therapeutics (AURX) has a PS Ratio of 11.04 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nuo Therapeutics and its competitors. This is 52% below median its historical median of 23.00. Over the past decade, Nuo Therapeutics' PS Ratio has ranged from 0.02 to 4,025.00. According to the industry distribution chart, Nuo Therapeutics ranks #496 out of 930 companies in the Biotechnology industry, placing it in the top 53.3%.
Is Nuo Therapeutics' PS Ratio too high?
Nuo Therapeutics' current PS Ratio of 11.04 is 52% below median its 10-year median of 23.00. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 4,025.00. The Biotechnology industry median PS Ratio is 9.52. Nuo Therapeutics' value of 11.04 is 16% above this industry median. Based on the distribution chart, Nuo Therapeutics ranks #496 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' PS Ratio compare to PDSB and LTRN?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #496 out of 930 companies for PS Ratio. This places Nuo Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.52. Nuo Therapeutics' value of 11.04 is 16% above this benchmark. Historically, Nuo Therapeutics' own PS Ratio has ranged from 0.02 to 4,025.00 over the past decade. While the company's 10-year median is 23.00 vs. the industry median of 9.52, Nuo Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuo Therapeutics's current PS Ratio of 11.04 is 16% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nuo Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuo Therapeutics's current PS Ratio is 11.04, which is 52% below median its own 10-year median of 23.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.29, compared to a current price of $0.96 — trading 77.6% below its estimated fair value. The current PS Ratio is 11.04, which is 52% below median its 10-year median of 23.00 and 16% above the Biotechnology industry median of 9.52. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current PS Ratio is 11.04 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuo Therapeutics (AURX) Overvalued in 2026?
Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued.
The current stock price of $0.96 is trading 77.6% below its estimated GF Value™ of $4.29.
GuruFocus considers Nuo Therapeutics to be Possible Value Trap.
Key valuation signals for AURX:
PS Ratio: 11.04 (52% below median its 10-year median of 23.00)
GF Value™: $4.29 vs. price of $0.96 (77.6% below fair value)
Industry Position: 16% above the Biotechnology median (#496 of 930)
No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score
Get the complete analysis for AURX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 
